Medicus Pharma Ltd ( (MDCX) ) has provided an announcement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Medicus Pharma Ltd. has completed the acquisition of Antev Limited, a UK-based clinical-stage drug development company, for approximately US$2.97 million in cash and 1,603,164 common shares. This acquisition enhances Medicus’s drug development pipeline with Teverelix, a next-generation GnRH antagonist aimed at treating acute urinary retention and high cardiovascular risk prostate cancer. The acquisition also strengthens Medicus’s board and management team, with key appointments including Patrick J. Mahaffy to the board of directors.
The most recent analyst rating on (MDCX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
More about Medicus Pharma Ltd
Medicus Pharma Ltd. is a biotech/life sciences company focused on advancing clinical development programs of novel and potentially disruptive therapeutic assets.
Average Trading Volume: 413,992
Technical Sentiment Signal: Sell
Current Market Cap: $34.56M
See more data about MDCX stock on TipRanks’ Stock Analysis page.